Meiragtx Holdings is a clinical stage gene therapy company. Co. focuses on: ocular diseases, including both inherited retinal diseases as well as degenerative ocular diseases; neurodegenerative diseases; and severe forms of xerostomia. Co.'s ophthalmology programs include Botaretigene Sparoparvovec for the treatment of X-linked retinitis pigmentosa associated with mutations in the retinitis pigmentosa GTPase regulator gene, which is an inherited retinal diseases which represent the genetic cause of blindness. Co.'s salivary gland programs include AAV-hAQP1 for the treatment of radiation-induced grade 2/3 xerostomia, which is a side effect of radiation treatment for head and neck cancer. The MGTX average annual return since 2018 is shown above.
The Average Annual Return on the MGTX average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MGTX average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MGTX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free MGTX Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
